APO Research
Talk to an analyst

APO RESEARCH · REPORT

Stem Cell Exosome Therapeutic

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Stem Cell Exosome Therapeutic Market Outlook and Growth Opportunities 2026

12 August 2026204 pages

Choose your research edition.

Industry ResearchStem Cell Exosome Therapeutic Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Stem Cell Exosome Therapeutic Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Stem Cell Exosome Therapeutic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Stem Cell Exosome Therapeutic Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Stem Cell Exosome Therapeutic Market Analysis and Forecast 2026-2032182 pages · $4,950 USD

Market perspective

The global Stem Cell Exosome Therapeutic market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Stem Cell Exosome Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Stem Cell Exosome Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Stem Cell Exosome Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Stem Cell Exosome Therapeutic market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Stem Cell Exosome Therapeutic market include CHA Biotech, ExoCoBio, Exopharm, OmniSpiant, BrainStorm Cell Therapeutics, Novadip Biosciences, Unicyte AG, Exogenus Therapeutics and Creative Medical Tech, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Stem Cell Exosome Therapeutic market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Stem Cell Exosome Therapeutic and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Stem Cell Exosome Therapeutic revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Stem Cell Exosome Therapeutic market.

Stem Cell Exosome Therapeutic Segment by Company

CHA Biotech

ExoCoBio

Exopharm

OmniSpiant

BrainStorm Cell Therapeutics

Novadip Biosciences

Unicyte AG

Exogenus Therapeutics

Creative Medical Tech

Anjarium Biosciences

Capricor Therapeutics

Kimera Labs ReNeuron

Stem Cell Medicine

Codiak Biosciencesare

Aegle Therapeutics

Brexogen

Cell Care Therapeutics

Stem Cell Exosome Therapeutic Segment by Type

Mesenchymal Stem Cell (MSC)

Dendritic Cells

Umbilical MSC

Others

Stem Cell Exosome Therapeutic Segment by Application

Precision Medicine

Regenerative Medicine

Others

Stem Cell Exosome Therapeutic Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Stem Cell Exosome Therapeutic status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Stem Cell Exosome Therapeutic key companies, revenue, market share, and recent developments.

3. To split the Stem Cell Exosome Therapeutic breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Stem Cell Exosome Therapeutic market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Stem Cell Exosome Therapeutic significant trends, drivers, influence factors in global and regions.

6. To analyze Stem Cell Exosome Therapeutic competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Stem Cell Exosome Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Stem Cell Exosome Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Stem Cell Exosome Therapeutic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Stem Cell Exosome Therapeutic industry.

Chapter 3: Detailed analysis of Stem Cell Exosome Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Stem Cell Exosome Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Stem Cell Exosome Therapeutic in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Stem Cell Exosome Therapeutic Industry Trends Table 2. Stem Cell Exosome Therapeutic Industry Drivers Table 3. Stem Cell Exosome Therapeutic Industry Opportunities and Challenges Table 4. Stem Cell Exosome Therapeutic Industry Restraints Table 5. Global Stem Cell Exosome Therapeutic Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Stem Cell Exosome Therapeutic Revenue Share by Company (2021-2026) Table 7. Global Stem Cell Exosome Therapeutic Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Stem Cell Exosome Therapeutic Key Company Manufacturing Base & Headquarters Table 9. Global Stem Cell Exosome Therapeutic Company, Product Type & Application Table 10. Global Stem Cell Exosome Therapeutic Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Stem Cell Exosome Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Mesenchymal Stem Cell (MSC) Table 15. Significant Companies of Dendritic Cells Table 16. Significant Companies of Umbilical MSC Table 17. Significant Companies of Others Table 18. Global Stem Cell Exosome Therapeutic Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Stem Cell Exosome Therapeutic Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Stem Cell Exosome Therapeutic Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Stem Cell Exosome Therapeutic Sales Value Share by Type (2021-2026) Table 22. Global Stem Cell Exosome Therapeutic Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Precision Medicine Table 24. Significant Companies of Regenerative Medicine Table 25. Significant Companies of Others Table 26. Global Stem Cell Exosome Therapeutic Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Stem Cell Exosome Therapeutic Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Stem Cell Exosome Therapeutic Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Stem Cell Exosome Therapeutic Sales Value Share by Application (2021-2026) Table 30. Global Stem Cell Exosome Therapeutic Sales Value Share by Application (2027-2032) Table 31. Global Stem Cell Exosome Therapeutic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Stem Cell Exosome Therapeutic Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Stem Cell Exosome Therapeutic Sales Value Share by Region (2021-2026) Table 34. Global Stem Cell Exosome Therapeutic Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Stem Cell Exosome Therapeutic Sales Value Share by Region (2027-2032) Table 36. Global Stem Cell Exosome Therapeutic Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Stem Cell Exosome Therapeutic Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Stem Cell Exosome Therapeutic Sales Value Market Share by Country (2021-2026) Table 39. Global Stem Cell Exosome Therapeutic Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Stem Cell Exosome Therapeutic Sales Value Market Share by Country (2027-2032) Table 41. CHA Biotech Company Information Table 42. CHA Biotech Business Overview Table 43. CHA Biotech Stem Cell Exosome Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. CHA Biotech Stem Cell Exosome Therapeutic Product Portfolio Table 45. CHA Biotech Recent Development Table 46. ExoCoBio Company Information Table 47. ExoCoBio Business Overview Table 48. ExoCoBio Stem Cell Exosome Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. ExoCoBio Stem Cell Exosome Therapeutic Product Portfolio Table 50. ExoCoBio Recent Development Table 51. Exopharm Company Information Table 52. Exopharm Business Overview Table 53. Exopharm Stem Cell Exosome Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Exopharm Stem Cell Exosome Therapeutic Product Portfolio Table 55. Exopharm Recent Development Table 56. OmniSpiant Company Information Table 57. OmniSpiant Business Overview Table 58. OmniSpiant Stem Cell Exosome Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. OmniSpiant Stem Cell Exosome Therapeutic Product Portfolio Table 60. OmniSpiant Recent Development Table 61. BrainStorm Cell Therapeutics Company Information Table 62. BrainStorm Cell Therapeutics Business Overview Table 63. BrainStorm Cell Therapeutics Stem Cell Exosome Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. BrainStorm Cell Therapeutics Stem Cell Exosome Therapeutic Product Portfolio Table 65. BrainStorm Cell Therapeutics Recent Development Table 66. Novadip Biosciences Company Information Table 67. Novadip Biosciences Business Overview Table 68. Novadip Biosciences Stem Cell Exosome Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Novadip Biosciences Stem Cell Exosome Therapeutic Product Portfolio Table 70. Novadip Biosciences Recent Development Table 71. Unicyte AG Company Information Table 72. Unicyte AG Business Overview Table 73. Unicyte AG Stem Cell Exosome Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Unicyte AG Stem Cell Exosome Therapeutic Product Portfolio Table 75. Unicyte AG Recent Development Table 76. Exogenus Therapeutics Company Information Table 77. Exogenus Therapeutics Business Overview Table 78. Exogenus Therapeutics Stem Cell Exosome Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Exogenus Therapeutics Stem Cell Exosome Therapeutic Product Portfolio Table 80. Exogenus Therapeutics Recent Development Table 81. Creative Medical Tech Company Information Table 82. Creative Medical Tech Business Overview Table 83. Creative Medical Tech Stem Cell Exosome Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Creative Medical Tech Stem Cell Exosome Therapeutic Product Portfolio Table 85. Creative Medical Tech Recent Development Table 86. Anjarium Biosciences Company Information Table 87. Anjarium Biosciences Business Overview Table 88. Anjarium Biosciences Stem Cell Exosome Therapeutic Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Anjarium Biosciences Stem Cell Exosome Therapeutic Product Portfolio Table 90. Anjarium Biosciences Recent Development Table 91. Capricor Therapeutics Company Information Table 92. Capricor Therapeutics Business Overview Table 93. Capricor Therapeutics Stem Cell Exosome Therapeutic Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Capricor Therapeutics Stem Cell Exosome Therapeutic Product Portfolio Table 95. Capricor Therapeutics Recent Development Table 96. Kimera Labs ReNeuron Company Information Table 97. Kimera Labs ReNeuron Business Overview Table 98. Kimera Labs ReNeuron Stem Cell Exosome Therapeutic Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Kimera Labs ReNeuron Stem Cell Exosome Therapeutic Product Portfolio Table 100. Kimera Labs ReNeuron Recent Development Table 101. Stem Cell Medicine Company Information Table 102. Stem Cell Medicine Business Overview Table 103. Stem Cell Medicine Stem Cell Exosome Therapeutic Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Stem Cell Medicine Stem Cell Exosome Therapeutic Product Portfolio Table 105. Stem Cell Medicine Recent Development Table 106. Codiak Biosciencesare Company Information Table 107. Codiak Biosciencesare Business Overview Table 108. Codiak Biosciencesare Stem Cell Exosome Therapeutic Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Codiak Biosciencesare Stem Cell Exosome Therapeutic Product Portfolio Table 110. Codiak Biosciencesare Recent Development Table 111. Aegle Therapeutics Company Information Table 112. Aegle Therapeutics Business Overview Table 113. Aegle Therapeutics Stem Cell Exosome Therapeutic Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Aegle Therapeutics Stem Cell Exosome Therapeutic Product Portfolio Table 115. Aegle Therapeutics Recent Development Table 116. Brexogen Company Information Table 117. Brexogen Business Overview Table 118. Brexogen Stem Cell Exosome Therapeutic Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Brexogen Stem Cell Exosome Therapeutic Product Portfolio Table 120. Brexogen Recent Development Table 121. Cell Care Therapeutics Company Information Table 122. Cell Care Therapeutics Business Overview Table 123. Cell Care Therapeutics Stem Cell Exosome Therapeutic Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Cell Care Therapeutics Stem Cell Exosome Therapeutic Product Portfolio Table 125. Cell Care Therapeutics Recent Development Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. Stem Cell Exosome Therapeutic Product Image Figure 2. Global Stem Cell Exosome Therapeutic Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Stem Cell Exosome Therapeutic Market Size (2021-2032) & (US$ Million) Figure 4. Global Stem Cell Exosome Therapeutic Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Mesenchymal Stem Cell (MSC) Image Figure 8. Dendritic Cells Image Figure 9. Umbilical MSC Image Figure 10. Others Image Figure 11. Global Stem Cell Exosome Therapeutic Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Stem Cell Exosome Therapeutic Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Stem Cell Exosome Therapeutic Sales Value Share by Type (2021-2032) Figure 14. Precision Medicine Image Figure 15. Regenerative Medicine Image Figure 16. Others Image Figure 17. Global Stem Cell Exosome Therapeutic Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Stem Cell Exosome Therapeutic Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Stem Cell Exosome Therapeutic Sales Value Share by Application (2021-2032) Figure 20. Global Stem Cell Exosome Therapeutic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Stem Cell Exosome Therapeutic Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Stem Cell Exosome Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 23. North America Stem Cell Exosome Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Stem Cell Exosome Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Stem Cell Exosome Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Stem Cell Exosome Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Stem Cell Exosome Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Stem Cell Exosome Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 29. South America Stem Cell Exosome Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Stem Cell Exosome Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Stem Cell Exosome Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Mesenchymal Stem Cell (MSC)
  • Dendritic Cells
  • Umbilical MSC
  • Others
Applications
  • Precision Medicine
  • Regenerative Medicine
  • Others
Companies covered
  • CHA Biotech
  • ExoCoBio
  • Exopharm
  • OmniSpiant
  • BrainStorm Cell Therapeutics
  • Novadip Biosciences
  • Unicyte AG
  • Exogenus Therapeutics
  • Creative Medical Tech
  • Anjarium Biosciences
  • Capricor Therapeutics
  • Kimera Labs ReNeuron
  • Stem Cell Medicine
  • Codiak Biosciencesare
  • Aegle Therapeutics
  • Brexogen
  • Cell Care Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Stem Cell Exosome Therapeutic Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Stem Cell Exosome Therapeutic Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Stem Cell Exosome Therapeutic Market Dynamics
  1. 2.1 Stem Cell Exosome Therapeutic Industry Trends
  2. 2.2 Stem Cell Exosome Therapeutic Industry Drivers
  3. 2.3 Stem Cell Exosome Therapeutic Industry Opportunities and Challenges
  4. 2.4 Stem Cell Exosome Therapeutic Industry Restraints
3 Stem Cell Exosome Therapeutic Market by Company
  1. 3.1 Global Stem Cell Exosome Therapeutic Company Revenue Ranking in 2025
  2. 3.2 Global Stem Cell Exosome Therapeutic Revenue by Company (2021-2026)
  3. 3.3 Global Stem Cell Exosome Therapeutic Company Ranking (2024-2026)
  4. 3.4 Global Stem Cell Exosome Therapeutic Company Manufacturing Base and Headquarters
  5. 3.5 Global Stem Cell Exosome Therapeutic Company Product Type and Application
  6. 3.6 Global Stem Cell Exosome Therapeutic Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Stem Cell Exosome Therapeutic Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Stem Cell Exosome Therapeutic Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Stem Cell Exosome Therapeutic Market by Type
  1. 4.1 Stem Cell Exosome Therapeutic Type Introduction
  2. 4.1.1 Mesenchymal Stem Cell (MSC)
  3. 4.1.2 Dendritic Cells
  4. 4.1.3 Umbilical MSC
  5. 4.1.4 Others
  6. 4.2 Global Stem Cell Exosome Therapeutic Sales Value by Type
  7. 4.2.1 Global Stem Cell Exosome Therapeutic Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Stem Cell Exosome Therapeutic Sales Value by Type (2021-2032)
  9. 4.2.3 Global Stem Cell Exosome Therapeutic Sales Value Share by Type (2021-2032)
5 Stem Cell Exosome Therapeutic Market by Application
  1. 5.1 Stem Cell Exosome Therapeutic Application Introduction
  2. 5.1.1 Precision Medicine
  3. 5.1.2 Regenerative Medicine
  4. 5.1.3 Others
  5. 5.2 Global Stem Cell Exosome Therapeutic Sales Value by Application
  6. 5.2.1 Global Stem Cell Exosome Therapeutic Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Stem Cell Exosome Therapeutic Sales Value by Application (2021-2032)
  8. 5.2.3 Global Stem Cell Exosome Therapeutic Sales Value Share by Application (2021-2032)
6 Stem Cell Exosome Therapeutic Regional Value Analysis
  1. 6.1 Global Stem Cell Exosome Therapeutic Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Stem Cell Exosome Therapeutic Sales Value by Region (2021-2032)
  3. 6.2.1 Global Stem Cell Exosome Therapeutic Sales Value by Region: 2021-2026
  4. 6.2.2 Global Stem Cell Exosome Therapeutic Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Stem Cell Exosome Therapeutic Sales Value (2021-2032)
  7. 6.3.2 North America Stem Cell Exosome Therapeutic Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Stem Cell Exosome Therapeutic Sales Value (2021-2032)
  10. 6.4.2 Europe Stem Cell Exosome Therapeutic Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Stem Cell Exosome Therapeutic Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Stem Cell Exosome Therapeutic Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Stem Cell Exosome Therapeutic Sales Value (2021-2032)
  16. 6.6.2 South America Stem Cell Exosome Therapeutic Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Stem Cell Exosome Therapeutic Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Stem Cell Exosome Therapeutic Sales Value Share by Country, 2025 VS 2032
7 Stem Cell Exosome Therapeutic Country-level Value Analysis
  1. 7.1 Global Stem Cell Exosome Therapeutic Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Stem Cell Exosome Therapeutic Sales Value by Country (2021-2032)
  3. 7.2.1 Global Stem Cell Exosome Therapeutic Sales Value by Country (2021-2026)
  4. 7.2.2 Global Stem Cell Exosome Therapeutic Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Stem Cell Exosome Therapeutic Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Stem Cell Exosome Therapeutic Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Stem Cell Exosome Therapeutic Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CHA Biotech
  2. 8.1.1 CHA Biotech Company Information
  3. 8.1.2 CHA Biotech Business Overview
  4. 8.1.3 CHA Biotech Stem Cell Exosome Therapeutic Revenue and Gross Margin (2021-2026)
  5. 8.1.4 CHA Biotech Stem Cell Exosome Therapeutic Product Portfolio
  6. 8.1.5 CHA Biotech Recent Developments
  7. 8.2 ExoCoBio
  8. 8.2.1 ExoCoBio Company Information
  9. 8.2.2 ExoCoBio Business Overview
  10. 8.2.3 ExoCoBio Stem Cell Exosome Therapeutic Revenue and Gross Margin (2021-2026)
  11. 8.2.4 ExoCoBio Stem Cell Exosome Therapeutic Product Portfolio
  12. 8.2.5 ExoCoBio Recent Developments
  13. 8.3 Exopharm
  14. 8.3.1 Exopharm Company Information
  15. 8.3.2 Exopharm Business Overview
  16. 8.3.3 Exopharm Stem Cell Exosome Therapeutic Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Exopharm Stem Cell Exosome Therapeutic Product Portfolio
  18. 8.3.5 Exopharm Recent Developments
  19. 8.4 OmniSpiant
  20. 8.4.1 OmniSpiant Company Information
  21. 8.4.2 OmniSpiant Business Overview
  22. 8.4.3 OmniSpiant Stem Cell Exosome Therapeutic Revenue and Gross Margin (2021-2026)
  23. 8.4.4 OmniSpiant Stem Cell Exosome Therapeutic Product Portfolio
  24. 8.4.5 OmniSpiant Recent Developments
  25. 8.5 BrainStorm Cell Therapeutics
  26. 8.5.1 BrainStorm Cell Therapeutics Company Information
  27. 8.5.2 BrainStorm Cell Therapeutics Business Overview
  28. 8.5.3 BrainStorm Cell Therapeutics Stem Cell Exosome Therapeutic Revenue and Gross Margin (2021-2026)
  29. 8.5.4 BrainStorm Cell Therapeutics Stem Cell Exosome Therapeutic Product Portfolio
  30. 8.5.5 BrainStorm Cell Therapeutics Recent Developments
  31. 8.6 Novadip Biosciences
  32. 8.6.1 Novadip Biosciences Company Information
  33. 8.6.2 Novadip Biosciences Business Overview
  34. 8.6.3 Novadip Biosciences Stem Cell Exosome Therapeutic Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novadip Biosciences Stem Cell Exosome Therapeutic Product Portfolio
  36. 8.6.5 Novadip Biosciences Recent Developments
  37. 8.7 Unicyte AG
  38. 8.7.1 Unicyte AG Company Information
  39. 8.7.2 Unicyte AG Business Overview
  40. 8.7.3 Unicyte AG Stem Cell Exosome Therapeutic Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Unicyte AG Stem Cell Exosome Therapeutic Product Portfolio
  42. 8.7.5 Unicyte AG Recent Developments
  43. 8.8 Exogenus Therapeutics
  44. 8.8.1 Exogenus Therapeutics Company Information
  45. 8.8.2 Exogenus Therapeutics Business Overview
  46. 8.8.3 Exogenus Therapeutics Stem Cell Exosome Therapeutic Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Exogenus Therapeutics Stem Cell Exosome Therapeutic Product Portfolio
  48. 8.8.5 Exogenus Therapeutics Recent Developments
  49. 8.9 Creative Medical Tech
  50. 8.9.1 Creative Medical Tech Company Information
  51. 8.9.2 Creative Medical Tech Business Overview
  52. 8.9.3 Creative Medical Tech Stem Cell Exosome Therapeutic Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Creative Medical Tech Stem Cell Exosome Therapeutic Product Portfolio
  54. 8.9.5 Creative Medical Tech Recent Developments
  55. 8.10 Anjarium Biosciences
  56. 8.10.1 Anjarium Biosciences Company Information
  57. 8.10.2 Anjarium Biosciences Business Overview
  58. 8.10.3 Anjarium Biosciences Stem Cell Exosome Therapeutic Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Anjarium Biosciences Stem Cell Exosome Therapeutic Product Portfolio
  60. 8.10.5 Anjarium Biosciences Recent Developments
  61. 8.11 Capricor Therapeutics
  62. 8.11.1 Capricor Therapeutics Company Information
  63. 8.11.2 Capricor Therapeutics Business Overview
  64. 8.11.3 Capricor Therapeutics Stem Cell Exosome Therapeutic Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Capricor Therapeutics Stem Cell Exosome Therapeutic Product Portfolio
  66. 8.11.5 Capricor Therapeutics Recent Developments
  67. 8.12 Kimera Labs ReNeuron
  68. 8.12.1 Kimera Labs ReNeuron Company Information
  69. 8.12.2 Kimera Labs ReNeuron Business Overview
  70. 8.12.3 Kimera Labs ReNeuron Stem Cell Exosome Therapeutic Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Kimera Labs ReNeuron Stem Cell Exosome Therapeutic Product Portfolio
  72. 8.12.5 Kimera Labs ReNeuron Recent Developments
  73. 8.13 Stem Cell Medicine
  74. 8.13.1 Stem Cell Medicine Company Information
  75. 8.13.2 Stem Cell Medicine Business Overview
  76. 8.13.3 Stem Cell Medicine Stem Cell Exosome Therapeutic Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Stem Cell Medicine Stem Cell Exosome Therapeutic Product Portfolio
  78. 8.13.5 Stem Cell Medicine Recent Developments
  79. 8.14 Codiak Biosciencesare
  80. 8.14.1 Codiak Biosciencesare Company Information
  81. 8.14.2 Codiak Biosciencesare Business Overview
  82. 8.14.3 Codiak Biosciencesare Stem Cell Exosome Therapeutic Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Codiak Biosciencesare Stem Cell Exosome Therapeutic Product Portfolio
  84. 8.14.5 Codiak Biosciencesare Recent Developments
  85. 8.15 Aegle Therapeutics
  86. 8.15.1 Aegle Therapeutics Company Information
  87. 8.15.2 Aegle Therapeutics Business Overview
  88. 8.15.3 Aegle Therapeutics Stem Cell Exosome Therapeutic Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Aegle Therapeutics Stem Cell Exosome Therapeutic Product Portfolio
  90. 8.15.5 Aegle Therapeutics Recent Developments
  91. 8.16 Brexogen
  92. 8.16.1 Brexogen Company Information
  93. 8.16.2 Brexogen Business Overview
  94. 8.16.3 Brexogen Stem Cell Exosome Therapeutic Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Brexogen Stem Cell Exosome Therapeutic Product Portfolio
  96. 8.16.5 Brexogen Recent Developments
  97. 8.17 Cell Care Therapeutics
  98. 8.17.1 Cell Care Therapeutics Company Information
  99. 8.17.2 Cell Care Therapeutics Business Overview
  100. 8.17.3 Cell Care Therapeutics Stem Cell Exosome Therapeutic Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Cell Care Therapeutics Stem Cell Exosome Therapeutic Product Portfolio
  102. 8.17.5 Cell Care Therapeutics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst